세계의 기능성 소화불량 치료제 시장 보고서(2025년)
Functional Dyspepsia Drug Global Market Report 2025
상품코드 : 1730871
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

기능성 소화불량 치료제 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 6.6%로 성장할 전망이며, 118억 달러로 성장이 예상됩니다. 예측 기간 동안의 성장은 포괄적이고 라이프스타일에 기초한 접근 방식에 대한 소비자 기호 증가, 병용 요법에 대한 기호 증가, 라이프스타일 수정의 채택 증가, 장뇌축에 관한 연구 확대, 비약리학적 개입의 사용 증가에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 약제 제형 진보, 헬스케어 공급자 및 제약기업 연계, 정밀의료 접근방식으로의 전환, 원격의료 및 디지털 헬스기술의 통합, 개별화 의료 전략 등을 들 수 있습니다.

알코올 소비량 증가가 기능성 소화불량 치료제 시장의 성장을 밀어 올릴 것으로 예측됩니다. 맥주, 와인, 증류주 등의 음료에 포함된 알코올은 에탄올로 구성되어 있으며 섭취 시 중추신경계에 영향을 미쳐 중독 증상을 일으킬 수 있습니다. 알코올 소비 증가는, 사회적 및 문화적 수용, 스트레스 해소, 입수의 용이성, 알코올 음료 회사에 의한 적극적인 마케팅 등의 요인에 의해서 초래되고 있습니다. 기능성 소화불량 치료제는 알코올로 인한 위의 불편함을 완화하기 위해 위산 분비를 억제하고 소화 기능을 개선하는 목적으로 사용됩니다. 예를 들어 영국 정부기관인 OHID(Office for Health Improvement & Disparities)가 2023년 3월 발표한 보고서에 따르면 2021-2022년 알코올에만 관련된 입원환자 수는 34만 2,795명으로 인구 10만 명당 입원환자 수는 626명에 이르는 것으로 나타났습니다. 이처럼 알코올 소비량의 증가가 기능성 소화불량 치료제 시장의 성장에 기여하고 있습니다.

대사성 질환의 유병률 증가는 기능성 소화불량 치료제 시장의 확대를 촉진할 것으로 예측됩니다. 대사장애는 체내의 정상적인 대사과정이 흐트러져 영양소와 에너지, 노폐물의 처리에 불균형이 생기면서 발생합니다. 식생활의 혼란, 앉기 쉬운 라이프 스타일, 유전적 소인, 비만율 상승 등의 요인이 이러한 질환의 유병률 상승에 기여하고 있습니다. 기능성 소화불량 치료제는 대사 장애를 가진 사람의 위장 증상을 관리하고 소화 기능을 개선하기 위해 사용됩니다. 예를 들어 세계보건기구(WHO)가 2024년 11월 발표한 보고서에 따르면 2022년에는 18세 이상 성인의 14%가 당뇨병 진단을 받았습니다. 따라서 대사성 질환의 유병률 상승이 기능성 소화불량 치료제 시장의 성장을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Functional dyspepsia drugs are a category of medications used to manage and relieve symptoms related to functional dyspepsia (FD), a gastrointestinal disorder marked by persistent or recurring upper abdominal discomfort without a clear structural or biochemical cause. These medications are designed to alleviate symptoms such as bloating, early satiety, nausea, and epigastric pain.

The primary types of drugs used to treat functional dyspepsia include proton pump inhibitors, H-2 receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. Proton pump inhibitors (PPIs) are a specific type of medication that reduce stomach acid production by inhibiting the action of the gastric proton pump (H+/K+-ATPase) in the stomach lining. These treatments are commonly used for functional dyspepsia as well as organic dyspepsia and are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The functional dyspepsia drug market research report is one of a series of new reports from The Business Research Company that provides functional dyspepsia drug market statistics, including the functional dyspepsia drug industry's global market size, regional shares, competitors with a functional dyspepsia drug market share, detailed functional dyspepsia drug market segments, market trends and opportunities, and any further data you may need to thrive in the functional dyspepsia drug industry. This functional dyspepsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The functional dyspepsia drug market size has grown strongly in recent years. It will grow from $8.56 billion in 2024 to $9.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing prevalence of various associated risk factors, higher healthcare expenditure, a rise in dyspeptic cases, a growing number of gastrointestinal disorders, and an expanding aging population.

The functional dyspepsia drug market size is expected to see strong growth in the next few years. It will grow to $11.80 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the rising consumer preference for holistic and lifestyle-based approaches, a growing preference for combination therapies, increased adoption of lifestyle modifications, expanding research on the gut-brain axis, and a higher use of non-pharmacological interventions. Key trends expected in this period include advancements in drug formulation, collaborations between healthcare providers and pharmaceutical companies, a shift toward precision medicine approaches, the integration of telemedicine and digital health technologies, and personalized medicine strategies.

The increase in alcohol consumption is expected to boost the growth of the functional dyspepsia drug market. Alcohol, found in beverages such as beer, wine, and spirits, is composed of ethanol, which affects the central nervous system and can cause intoxication when consumed. The rising consumption of alcohol is driven by factors such as social and cultural acceptance, stress relief, easy availability, and aggressive marketing by alcoholic beverage companies. Functional dyspepsia drugs are used to alleviate alcohol-induced gastric discomfort by reducing acid production and improving digestive function. For example, a report published by the Office for Health Improvement & Disparities (OHID) in March 2023, a UK-based government agency, revealed that between 2021 and 2022, there were 342,795 hospital admissions related solely to alcohol, leading to a rate of 626 admissions per 100,000 people. Thus, the increase in alcohol consumption is contributing to the growth of the functional dyspepsia drug market.

The rise in the prevalence of metabolic disorders is expected to drive the expansion of the functional dyspepsia drug market. A metabolic disorder occurs when the body's normal metabolic processes are disrupted, leading to an imbalance in the processing of nutrients, energy, or waste. Factors such as poor diet, sedentary lifestyles, genetic predispositions, and rising obesity rates contribute to the growing prevalence of these disorders. Functional dyspepsia drugs are used to manage gastrointestinal symptoms and improve digestive function in individuals with metabolic disorders. For instance, a report published by the World Health Organization (WHO) in November 2024 stated that 14% of adults aged 18 and older were diagnosed with diabetes in 2022. Therefore, the rising prevalence of metabolic disorders is driving the growth of the functional dyspepsia drug market.

Leading companies in the functional dyspepsia drug market are focusing on clinical trials to develop innovative therapies that address the underlying causes of the condition, improve treatment effectiveness, and meet patient needs. Clinical trials are crucial for assessing the safety, efficacy, and optimal treatment strategies for functional dyspepsia drugs. For example, in December 2022, electroCore Inc., a US-based medical technology company, announced that the United States Patent and Trademark Office (USPTO) granted two patents for its innovative non-invasive vagus nerve stimulation (nVNS) technology. The first patent, U.S. Patent No. 11,511,109, covered a method for treating gastrointestinal disorders, including functional dyspepsia, using vagus nerve stimulation. The second patent, U.S. Patent No. 11,511,110, involved a system for delivering non-invasive electrical stimulation to the vagus nerve. These patents reinforced electroCore's position in advancing non-invasive neuromodulation therapies.

Major players in the functional dyspepsia drug market are Pfizer Inc., Abbvie Inc., Bayer AG, AstraZeneca plc, Astellas Pharma Inc., Eisai Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Lupin Limited, Daewoong Pharmaceutical Co. Ltd., Phathom Pharmaceuticals, Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Salix Pharmaceuticals Inc., RedHill Biopharma, RaQualia Pharma Inc., MetaMe Health, Renexxion LLC, Processa Pharmaceuticals, and Evoke Pharma Inc.

North America was the largest region in the functional dyspepsia drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in functional dyspepsia drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the functional dyspepsia drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The functional dyspepsia drug market consists of sales of mucosal protectants, neuromodulators, serotonin modulators, and herbal drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Functional Dyspepsia Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on functional dyspepsia drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for functional dyspepsia drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The functional dyspepsia drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Functional Dyspepsia Drug Market Characteristics

3. Functional Dyspepsia Drug Market Trends And Strategies

4. Functional Dyspepsia Drug Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Functional Dyspepsia Drug Growth Analysis And Strategic Analysis Framework

6. Functional Dyspepsia Drug Market Segmentation

7. Functional Dyspepsia Drug Market Regional And Country Analysis

8. Asia-Pacific Functional Dyspepsia Drug Market

9. China Functional Dyspepsia Drug Market

10. India Functional Dyspepsia Drug Market

11. Japan Functional Dyspepsia Drug Market

12. Australia Functional Dyspepsia Drug Market

13. Indonesia Functional Dyspepsia Drug Market

14. South Korea Functional Dyspepsia Drug Market

15. Western Europe Functional Dyspepsia Drug Market

16. UK Functional Dyspepsia Drug Market

17. Germany Functional Dyspepsia Drug Market

18. France Functional Dyspepsia Drug Market

19. Italy Functional Dyspepsia Drug Market

20. Spain Functional Dyspepsia Drug Market

21. Eastern Europe Functional Dyspepsia Drug Market

22. Russia Functional Dyspepsia Drug Market

23. North America Functional Dyspepsia Drug Market

24. USA Functional Dyspepsia Drug Market

25. Canada Functional Dyspepsia Drug Market

26. South America Functional Dyspepsia Drug Market

27. Brazil Functional Dyspepsia Drug Market

28. Middle East Functional Dyspepsia Drug Market

29. Africa Functional Dyspepsia Drug Market

30. Functional Dyspepsia Drug Market Competitive Landscape And Company Profiles

31. Functional Dyspepsia Drug Market Other Major And Innovative Companies

32. Global Functional Dyspepsia Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Functional Dyspepsia Drug Market

34. Recent Developments In The Functional Dyspepsia Drug Market

35. Functional Dyspepsia Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기